Melanie Senior
Spain’s Almirall SA may have listed only 30% of its share capital at its June 2007 IPO, but the...
Almirall: Adapting Primary-Care-focused R&D to a Specialist World
Late-stage COPD candidate aclidinium could transform mid-sized Almirall. This is what’s exciting the dozen or more analysts that cover such long-acting muscarinic antagonists; it’s the potential $2 billion drug that “could double or treble the size of this company in a very short time,” sums up one analyst. At the same time, the newly-listed company's other challenge is to monetize the fruits of its primary-care-focused R&D in a world that's going specialist.
More from Business Strategy
• By
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
• By
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
• By
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
• By
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
More from In Vivo
• By
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
• By
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
• By
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.